» Articles » PMID: 33098868

MiR-34a Regulates Lipid Metabolism by Targeting SIRT1 in Non-alcoholic Fatty Liver Disease with Iron Overload

Overview
Publisher Elsevier
Specialties Biochemistry
Biophysics
Date 2020 Oct 25
PMID 33098868
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Micro-ribonucleic acids (miRNAs) have been implicated in the regulation of non-alcoholic fatty liver disease (NAFLD), a leading cause of chronic liver disease worldwide. The mechanisms by which miR-34a influences NAFLD through the Sirtuin 1 (SIRT1)-related pathway were investigated herein.

Methods: Male C57BL/6 mice were injected with a miR-34a lentivirus vector inhibitor or control. HepG2 cells were transfected with a miR-34a mimic, inhibitor, SIRT1 small interfering RNA (siRNA), SIRT1 plasmid, and a negative oligonucleotide control to evaluate their role in oleic acid (OA) and excess iron-induced NAFLD. The accumulation of lipids in the mice liver and HepG2 cells was analyzed by triglyceride (TG) detection and hematoxylin and eosin (HE) staining. Additionally, the indexes of oxidative stress related to lipid metabolism were evaluated by western blotting and real-time PCR (qRT-PCR). The levels of intracellular reactive oxygen species (ROS) and mitochondrial membrane potentials were measured by flow cytometry and laser confocal microscopy, respectively. Finally, the dual luciferase reporter assay was conducted to further confirm whether SIRT1 was a direct target of miR-34a.

Results: Overexpression of miR-34a resulted in increased triglyceride accumulation as well as in decreased mitochondrial membrane potential and SIRT1 levels. Silencing of miR-34a increased SIRT1 expression and alleviated triglyceride accumulation in the presence of OA and iron. Additionally, miR-34a directly inhibited SIRT1 by binding to the 3'-untranslated region, as determined via the luciferase reporter assay.

Conclusions: Our results support the existence of a link between the liver cell mitochondria and miR-34a/SIRT1 signaling. Potential endogenous modulators of NAFLD pathogenesis may ultimately provide new tools for therapeutic intervention.

Citing Articles

Exploring the Role of Metabolic Hyperferritinaemia (MHF) in Steatotic Liver Disease (SLD) and Hepatocellular Carcinoma (HCC).

Anastasopoulos N, Barbouti A, Goussia A, Christodoulou D, Glantzounis G Cancers (Basel). 2025; 17(5).

PMID: 40075688 PMC: 11899477. DOI: 10.3390/cancers17050842.


The Role of MicroRNAs in Liver Functioning: from Biogenesis to Therapeutic Approaches (Review).

Kozlov D, Rodimova S, Kuznetsova D Sovrem Tekhnologii Med. 2025; 15(5):54-79.

PMID: 39967915 PMC: 11832066. DOI: 10.17691/stm2023.15.5.06.


From fatty liver to fibrosis: the impact of miRNAs on NAFLD and NASH.

Mansour R, Mageed S, Abulsoud A, Sayed G, Lutfy R, Awad F Funct Integr Genomics. 2025; 25(1):30.

PMID: 39888504 DOI: 10.1007/s10142-025-01544-x.


Gut Microbiota-microRNA Interactions and Obesity Pathophysiology: A Systematic Review of Integrated Studies.

Azari H, George M, Albracht-Schulte K Int J Mol Sci. 2024; 25(23).

PMID: 39684547 PMC: 11640985. DOI: 10.3390/ijms252312836.


The Development of a Non-Invasive Screening Method Based on Serum microRNAs to Quantify the Percentage of Liver Steatosis.

Soluyanova P, Quintas G, Perez-Rubio A, Rienda I, Moro E, van Herwijnen M Biomolecules. 2024; 14(11).

PMID: 39595599 PMC: 11592063. DOI: 10.3390/biom14111423.